Management of antithrombotic agents in patients undergoing flexible bronchoscopy.
Eur Respir Rev
; 26(145)2017 Sep 30.
Article
en En
| MEDLINE
| ID: mdl-28724561
Bleeding is one of the most feared complications of flexible bronchoscopy. Although infrequent, it can be catastrophic and result in fatal outcomes. Compared to other endoscopic procedures, the risk of morbidity and mortality from the bleeding is increased, as even a small amount of blood can fill the tracheobronchial tree and lead to respiratory failure. Patients using antithrombotic agents (ATAs) have higher bleeding risk. A thorough understanding of the different ATAs is critical to manage patients during the peri-procedural period. A decision to stop an ATA before bronchoscopy should take into account a variety of factors, including indication for its use and the type of procedure. This article serves as a detailed review on the different ATAs, their pharmacokinetics and the pre- and post-bronchoscopy management of patients receiving these medications.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Broncoscopía
/
Inhibidores de Agregación Plaquetaria
/
Fibrinolíticos
/
Hemorragia
/
Anticoagulantes
Tipo de estudio:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Eur Respir Rev
Año:
2017
Tipo del documento:
Article
País de afiliación:
Estados Unidos